- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
This study is testing a new inhaler for adults with asthma that isn't well controlled. It compares a new triple-medicine inhaler to existing ones to see if it works better at preventing asthma attacks and improving breathing over 24-52 weeks.
For: Severe and inadequately controlled asthmaSpain · Romania · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
This study is looking at a new medicine called Tozorakimab for people with COPD. It aims to see if it can reduce severe flare-ups and if it's safe. Participants will be compared to those taking a dummy medicine.
For: Chronic Obstructive Pulmonary Disease (COPD)Czechia · Denmark · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
This study is looking at new inhalers for adults with asthma that isn't well-controlled. It aims to see if a new combination inhaler works better than current ones to improve breathing and reduce asthma attacks.
For: Severe and inadequately controlled asthmaPortugal · Greece · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)
This study is testing a new medicine, Tozorakimab, for people with severe COPD who often have flare-ups. We want to see if it reduces these flare-ups and is safe to use. Some people will get the new medicine, others a dummy medicine (placebo).
For: Chronic Obstructive Pulmonary Disease (COPD)Poland · Germany · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients with Pseudomonas Aeruginosa (Pa) or other Potentially Pathogenic Micro-organisms (PPMs).
This study is testing a new inhaled medicine, RESP30X, for people with a lung condition called non-cystic fibrosis bronchiectasis. We want to see if it's safe, how well people tolerate it, and if it helps fight common lung infections like *Pseudomonas aeruginosa*.
For: Non-Cystic Fibrosis Bronchiectasis with Pseudomonas Aeruginosa or other Potentially Pathogenic Micro-organismsRomania · Bulgaria · Poland - Active not recruitingPHASE3
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
This study looks at how well a new asthma medicine, tezepelumab, works to control severe asthma while patients try to reduce their regular asthma inhaler use. It aims to see if patients can stay well on less medicine.
For: Severe AsthmaUnited States · Argentina · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma (VATHOS)
This study looks at new ways to treat asthma that isn't well controlled. It compares different inhaler medicines to see which ones work best and are safest for adults. The goal is to help people with asthma breathe easier.
For: Inadequately Controlled AsthmaSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy
This three-year study is looking at a new medicine called ligelizumab for food allergy. It's checking how safe it is and how well it works over a long time in people who have already taken part in earlier studies for this medicine.
For: Food allergyNetherlands · France · Spain - Ongoing, recruitingPhase III and phase IV (Integrated)
A Double Blind, Multicentre, Randomised Three-Period, Three-Treatment, Cross-Over Study To Evaluate The Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters In Participants with Chronic Obstructive Pulmonary Disease (ATHLOS)
This study is looking at a new inhaler treatment called Trixeo Aerosphere for people with a lung condition called Chronic Obstructive Pulmonary Disease (COPD). It compares it to another inhaler and a dummy inhaler to see if it helps people exercise more easily.
For: Chronic Obstructive Pulmonary DiseaseGermany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthma
This study is testing a new version of an asthma inhaler (CHF5993) to see if it's safe for people aged 18 and over with moderate to severe asthma. It compares the new version against an existing one over 12 weeks to ensure it works just as well and has similar side effects.
For: Moderate to severe controlled asthma according to Step 4 and Step 5 of the Global Initiative for Asthma (GINA) 2022 Guidelines.Poland · Germany · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)
This study is testing a new medicine, tozorakimab, for people with lung disease called COPD. It wants to see if this medicine can help reduce flare-ups of COPD. Some people will get the new medicine, and others will get a dummy medicine, alongside their usual care.
For: Chronic Obstructive Pulmonary Disease (COPD)Greece · Denmark · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease
This study is testing different versions of an inhaler treatment for moderate to severe COPD. It wants to see if a new design works as well as the current one, and if both are better than using a dummy inhaler. We're looking at how well people can breathe.
For: Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)Hungary · Bulgaria · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma
This study is testing a new medicine, Atuliflapon, for adults whose moderate-to-severe asthma isn't well controlled by their usual treatments. We want to see if it reduces asthma flare-ups and improves breathing, compared to a dummy pill, over 12 weeks.
For: Moderate-to-Severe Uncontrolled AsthmaPoland · Croatia · Bulgaria - Ongoing, recruitingPhase III and phase IV (Integrated)
Evaluation of frequency occurrence persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy treated by salbutamol
This study looks at how often a lung problem called PPHN happens in babies born between 32 and 42 weeks, when they are given a medicine called salbutamol for breathing difficulties. Researchers want to see if salbutamol affects their breathing.
For: Breathing disorders as a cause of neonatal respiratory failurePoland - AuthorisedTherapeutic use (Phase IV)
Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT
This study looks at different inhalers to help young children who get wheezy sometimes. Researchers want to find the best way to control their symptoms and make them feel better, using medicines already available. It's about finding the easiest and most helpful treatments for these children.
For: Episodic expiratory wheezingNetherlands